Zoetis: stocks, financial statements

Dividends News

It is the world's largest manufacturer of medicines and vaccines for Pets and livestock. It was a subsidiary of Pfizer. The activity is aimed at providing medicines to livestock producers, livestock farms, veterinarians, as well as individuals caring for agricultural Pets. Medicines are intended for sheep and pigs, cattle, poultry and fish. In addition, there is a separate line of products for cats and dogs. Operations outside the United States accounted for 50% of total revenue. Products also consist of vaccines, parasites and infections, feed additives, diagnostic (biochemical tests, appropriate equipment) and pharmaceuticals.

28 sites in 11 countries make up the company's production network, each of which is designed to meet the safety requirements of chemical and infectious agents. Many R&D operations are combined with production sites, which allows you to quickly bring new products to market.

  • ZTS Ticker
  • NYSE Exchange
  • 10,000 Employees
7 rated

Financial statements — Zoetis

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
6.7B 6.3B 5.8B 5.3B 4.9B
Cost Of Revenue
2.1B 2B 1.9B 1.8B 1.7B
Gross Profit
4.6B 4.3B 3.9B 3.5B 3.2B
Research and Development
460M 460M 430M 380M 380M
Selling General and Admin
1.7B 1.6B 1.5B 1.3B 1.4B
Operating Expense
4.4B 4.2B 3.9B 3.6B 3.5B
Operating Income
2.3B 2B 1.9B 1.7B 1.4B
Other Income Expense Net
12M 16M 28M 12M 30M
2.3B 2B 1.9B 1.7B 1.4B
Interest Income
220M 190M 180M 180M 170M
Pretax Income
2B 1.8B 1.7B 1.5B 1.2B
Income Tax
360M 300M 270M 660M 410M
Minority Interest
-2M 0 -4M -2M -2M
Net Income
1.6B 1.5B 1.4B 860M 820M
Net Income Basic
1.6B 1.5B 1.4B 860M 820M
20 ← 16 2020 2019 2018 2017 2016
Current cash
3.6B 1.9B 1.7B 1.6B 730M
Short term investments
370M 320M 270M 230M 250M
1B 1.1B 1B 1M 910M
1.6B 1.4B 1.4B 1.4B 1.5B
Other current assets
370M 320M 270M 230M 250M
Current assets
6.6B 4.7B 4.4B 4.2B 3.4B
Long term investments
7B 6.8B 6.4B 4.4B 4.3B
Property plant equipment
2.2B 1.9B 1.7B 1.4B 1.4B
2.7B 2.6B 2.5B 1.5B 1.5B
Intangible assets
1.7B 1.9B 2B 1.3B 1.2B
Other assets
110M 98M 94M 75M 73M
Total assets
14B 12B 11B 8.6B 7.6B
Accounts payable
460M 300M 310M 260M 270M
Current long term debt
600M 500M 9M 0 0
Other current liabilities
1.1B 1B 900M 830M 850M
Total current liabilities
2.2B 1.8B 1.2B 1.1B 1.1B
Long term debt
6.6B 5.9B 6.4B 5B 4.5B
Other liabilities
530M 490M 450M 370M 320M
Minority Interest
4M 0 0 16M 12M
Total Liabilities
9.8B 8.8B 8.6B 6.8B 6.2B
Common stock
480M 480M 480M 490M 500M
Retained earning
5.7B 4.4B 3.3B 2.1B 1.5B
Treasury stock
-2.2B -2B -1.5B -850M -420M
Capital surplus
Shareholder equity
3.8B 2.7B 2.2B 1.8B 1.5B
Net tangible assets
-640M -1.8B -2.4B -1B -1.2B
20 ← 16 2020 2019 2018 2017 2016
Net Income
1.6B 1.5B 1.4B 860M 820M
440M 410M 310M 240M 240M
Changes in receivables
-73M 50M 38M 85M -24M
Changes in inventories
220M 19M -36M -75M 35M
Cash change
1.7B 230M 140M 840M -430M
Cash flow
2.1B 1.8B 1.8B 1.3B 710M
Capital expenditures
-450M -460M -340M -220M -220M
Investing activity other
Total investing cash flows
-570M -500M -2.3B -270M -210M
Dividends paid
Net borrowings
3.2B 4.2B 4.5B 3.2B 3.5B
Other financing cash flows
Cash flow financing
120M -950M 530M -250M -900M
Exchange rate effect